Peter Hillmen

Q: What Schools Are Affiliated With Peter Hillmen

Peter Hillmen is affiliated with the following schools: Australian National University, University of Cambridge, Saarland University, University of Leeds, Imperial College London, Medical University of Lublin, University of Oxford, Royal Postgraduate Medical School

Peter Hillmen's AcademicInfluence.com Rankings

Peter Hillmen

Biology

#8346

World Rank

#11409

Historical Rank

Immunology

#474

World Rank

#491

Historical Rank

Molecular Biology

#1049

World Rank

#1073

Historical Rank

Biochemistry

#1203

World Rank

#1322

Historical Rank

biology Degrees

Download Badge

Biology

Peter Hillmen's Degrees

PhD Biomedical Sciences University of Oxford

Why Is Peter Hillmen Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Peter Hillmen's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. (2008) (3147)
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. (2014) (1570)
The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. (2005) (1399)
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. (2014) (1363)
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. (2015) (1185)
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. (2002) (1010)
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. (2018) (874)
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. (2006) (868)
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. (2016) (707)
Diagnosis and management of paroxysmal nocturnal hemoglobinuria. (2005) (705)
Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. (2007) (607)
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. (2010) (596)
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial (2007) (592)
Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. (2004) (571)
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia (2018) (564)
Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. (2008) (550)
Natural history of paroxysmal nocturnal hemoglobinuria. (1995) (529)
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. (2007) (506)
Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. (2008) (466)
Guidelines for the diagnosis and management of adult aplastic anaemia (2016) (442)
Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. (2005) (431)
Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. (2010) (417)
Diagnostic criteria for monoclonal B‐cell lymphocytosis (2005) (395)
A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia (2008) (380)
Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG‐A gene. (1994) (360)
Thrombosis in paroxysmal nocturnal hemoglobinuria. (2013) (358)
International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia (2007) (352)
Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. (2002) (346)
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010) (337)
Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial (2015) (311)
Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria (2013) (307)
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. (2016) (277)
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study (2019) (266)
Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. (2001) (263)
Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). (2003) (261)
Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (2019) (236)
Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion. (2002) (234)
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. (2018) (226)
Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. (2005) (221)
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. (2018) (211)
Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. (2019) (206)
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL (2017) (205)
SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage. (2014) (203)
ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia (2012) (199)
Hypomorphic promoter mutation in PIGM causes inherited glycosylphosphatidylinositol deficiency (2006) (198)
Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. (2002) (196)
Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. (2004) (189)
ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells. (2016) (186)
Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial. (2012) (184)
Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. (2005) (183)
Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials (2017) (182)
A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study (2015) (180)
Somatic mutations and cellular selection in paroxysmal nocturnal haemoglobinuria (1994) (179)
Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry (2014) (177)
Long‐term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria (2010) (173)
Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL (2013) (171)
Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization (2010) (162)
Guidelines on the diagnosis and management of chronic lymphocytic leukaemia (2004) (154)
Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. (2019) (150)
Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study (2019) (150)
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. (2019) (148)
Application of flow cytometry to the diagnosis of paroxysmal nocturnal hemoglobinuria. (2000) (141)
Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia (2012) (139)
Effect of eculizumab on haemolysis‐associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria (2010) (138)
Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria (2007) (133)
Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. (2019) (131)
The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab (2010) (124)
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2020) (123)
Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10‐year pharmacovigilance analysis (2019) (122)
Idelalisib or Placebo in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL - Interim Results of a Phase 3 Randomized, Double-blind Placebo-Controlled Trial (2017) (121)
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial (2021) (120)
Specific defect in N-acetylglucosamine incorporation in the biosynthesis of the glycosylphosphatidylinositol anchor in cloned cell lines from patients with paroxysmal nocturnal hemoglobinuria. (1993) (119)
Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study. (2014) (118)
Defining the pathogenic role of telomerase mutations in myelodysplastic syndrome and acute myeloid leukemia (2009) (116)
Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response. (2007) (111)
Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project (2015) (111)
Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL. (2015) (110)
Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (2018) (110)
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. (2021) (109)
Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study (2020) (108)
Minimal residual disease is an independent predictor for 10-year survival in CLL. (2016) (106)
Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. (2019) (105)
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. (2017) (104)
Immune-mediated hemolytic anemia. (2004) (102)
Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2 (2018) (102)
Different biology and clinical outcome according to the absolute numbers of clonal B‐cells in monoclonal B‐cell lymphocytosis (MBL) (2010) (99)
Mutations in the PIG-A gene causing paroxysmal nocturnal hemoglobinuria are mainly of the frameshift type. (1995) (96)
Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. (2004) (95)
Ofatumumab + Chlorambucil Versus Chlorambucil Alone In Patients With Untreated Chronic Lymphocytic Leukemia (CLL): Results Of The Phase III Study Complement 1 (OMB110911) (2013) (91)
Second Interim Analysis of a Phase 3 Study of Idelalisib (ZYDELIG®) Plus Rituximab (R) for Relapsed Chronic Lymphocytic Leukemia (CLL): Efficacy Analysis in Patient Subpopulations with Del(17p) and Other Adverse Prognostic Factors (2014) (91)
Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia (2021) (90)
IMPLICATIONS OF RECENT INSIGHTS INTO THE PATHOPHYSIOLOGY OF PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA (2000) (78)
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. (2019) (78)
Mutations in the PIG‐A gene causing partial deficiency of GPI‐linked surface proteins (PNH II) in patients with paroxysmal nocturnal haemoglobinuria (1994) (71)
Genomic organization of the X-linked gene (PIG-A) that is mutated in paroxysmal nocturnal haemoglobinuria and of a related autosomal pseudogene mapped to 12q21. (1994) (67)
Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia (2016) (66)
Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia. (2004) (66)
Tissue plasminogen activator for hepatic vein thrombosis in paroxysmal nocturnal haemoglobinuria (1994) (66)
The Incidence and Prevalence of Paroxysmal Nocturnal Hemoglobinuria (PNH) and Survival of Patients in Yorkshire. (2006) (66)
Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. (2016) (64)
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia (2012) (62)
Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma (2018) (58)
Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single‐agent ibrutinib (2017) (57)
Recent advances in the diagnosis, monitoring, and management of patients with paroxysmal nocturnal hemoglobinuria (2007) (57)
Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria (2008) (56)
Paroxysmal nocturnal hemoglobinuria--hemolysis before and after eculizumab. (2010) (54)
Under‐recognized complications in patients with paroxysmal nocturnal haemoglobinuria: raised pulmonary pressure and reduced right ventricular function (2012) (54)
Protection of erythrocytes from human complement-mediated lysis by membrane-targeted recombinant soluble CD59: a new approach to PNH therapy. (2006) (53)
Characterization of breakthrough hemolysis events observed in the phase III randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria (2020) (53)
Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion (2020) (53)
Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim Analysis of An International Pivotal Trial (2008) (52)
Improvement in the symptoms of smooth muscle dystonia during eculizumab therapy in paroxysmal nocturnal hemoglobinuria. (2005) (51)
Efficacy and Safety of Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia with 17p Deletion: Results from the Phase II RESONATE™-17 Trial (2014) (49)
USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional status. (2017) (49)
Paroxysmal nocturnal haemoglobinuria: Nature's gene therapy? (2002) (48)
Changing prognosis in paroxysmal nocturnal haemoglobinuria disease subcategories: an analysis of the International PNH Registry (2016) (47)
ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. (2020) (46)
A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia (2011) (46)
Two distinct patterns of glycosylphosphatidylinositol (GPI) linked protein deficiency in the red cells of patients with paroxysmal nocturnal haemoglobinuria (1992) (46)
Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study (2017) (45)
Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (2016) (45)
Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. (2019) (45)
Production and characterization of lymphoblastoid cell lines with the paroxysmal nocturnal hemoglobinuria phenotype. (1993) (44)
Rituximab Plus Chlorambucil In Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukemia (CLL): Final Response Analysis of An Open-Label Phase II Study (2010) (44)
Using the biology of chronic lymphocytic leukemia to choose treatment. (2011) (43)
Development and evaluation of a stabilized whole‐blood preparation as a process control material for screening of paroxysmal nocturnal hemoglobinuria by flow cytometry (2009) (43)
The biological and clinical relationship between CD5+23+ monoclonal B‐cell lymphocytosis and chronic lymphocytic leukaemia (2007) (43)
Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice (2018) (42)
Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations. (2019) (42)
Alemtuzumab therapy in B-cell lymphoproliferative disorders. (2003) (42)
Lymphocyte subset analysis and glycosylphosphatidylinositol phenotype in patients with paroxysmal nocturnal hemoglobinuria. (1998) (42)
Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx) (2020) (41)
Initial Results of Ibrutinib Plus Venetoclax in Relapsed, Refractory CLL (Bloodwise TAP CLARITY Study): High Rates of Overall Response, Complete Remission and MRD Eradication after 6 Months of Combination Therapy (2017) (41)
Monoclonal B-cell lymphocytosis (MBL) in CLL families: substantial increase in relative risk for young adults (2006) (41)
Flow cytometric protein expression profiling as a systematic approach for developing disease-specific assays: identification of a chronic lymphocytic leukaemia-specific assay for use in rituximab-containing regimens (2006) (41)
NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome (2016) (41)
Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced‐stage, relapsed chronic lymphocytic leukaemia (2009) (38)
Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a Phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia (2015) (37)
Idelalisib Plus Bendamustine and Rituximab (BR) Is Superior to BR Alone in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results of a Phase 3 Randomized Double-Blind Placebo-Controlled Study (2015) (37)
B‐cell chronic lymphocytic leukaemia cells show specific changes in membrane protein expression during different stages of cell cycle (2007) (37)
Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials (2018) (36)
Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia (2020) (35)
Chronic lymphocytic leukaemia (CLL) and CLL‐type monoclonal B‐cell lymphocytosis (MBL) show differential expression of molecules involved in lymphoid tissue homing (2010) (34)
Early Results from LRF CLL4: A UK Multicenter Randomized Trial. (2005) (33)
Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia - Results from Pre-Planned Interim Analysis of the Randomized Phase 3 Murano Study (2017) (33)
Acalabrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia. (2021) (33)
Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Results from Arm C of the Sequoia (BGB-3111-304) Trial (2019) (33)
Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia. (2020) (33)
Primary thrombocythaemia in pregnancy (1991) (33)
Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial (2017) (32)
Factor V Leiden mutation investigated by amplification created restriction enzyme site (ACRES) in PNH patients with and without thrombosis. (1996) (32)
Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies (2020) (32)
The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab (2009) (32)
Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia (2015) (32)
The evolving role of Alemtuzumab in management of patients with CLL (2005) (31)
Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP (2005) (31)
Updated Efficacy Including Genetic and Clinical Subgroup Analysis and Overall Safety in the Phase 3 RESONATETM Trial of Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (2014) (31)
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia. (2019) (31)
Acalabrutinib Monotherapy in Patients with Richter Transformation from the Phase 1/2 ACE-CL-001 Clinical Study (2016) (31)
A Multi-Center, Open-Label, Phase I Study of Single Agent RG7112, A First In Class p53-MDM2 Antagonist, In Patients with Relapsed/Refractory Acute Myeloid and Lymphoid Leukemias (AML/ALL) and Refractory Chronic Lymphocytic Leukemia/Small Cell Lymphocytic Lymphomas (CLL/SCLL) (2010) (31)
Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (2018) (30)
Comparing Single-Agent Ibrutinib, Bendamustine Plus Rituximab (BR) and Ibrutinib Plus BR in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): An Indirect Comparison of the RESONATE and HELIOS Trials (2015) (30)
The management of paroxysmal nocturnal hemoglobinuria: recent advances in diagnosis and treatment and new hope for patients. (2009) (30)
Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Results from the Phase 1/2 ACE-CL-001 Study (2017) (30)
Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL (2017) (30)
Safety and Efficacy of a Combination of Venetoclax (GDC-0199/ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331) (2015) (29)
The role of complement inhibition in PNH. (2008) (29)
First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia. (2021) (29)
Cross‐sectional validation study of patient‐reported outcomes in patients with paroxysmal nocturnal haemoglobinuria (2013) (29)
Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study (2018) (28)
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia (2022) (28)
A randomized, open‐label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia (2014) (28)
The Light Chain IgLV3-21 Defines a New Poor Prognostic Subgroup in Chronic Lymphocytic Leukemia: Results of a Multicenter Study (2018) (28)
The Glycosylphosphatidylinositol Anchor and Paroxysmal Nocturnal Haemoglobinuria/Aplasia Model (2002) (27)
Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL (2017) (27)
Minimal residual disease in chronic lymphocytic leukaemia: is it ready for primetime? (2007) (27)
Pooled Analysis of Safety Data from Clinical Trials Evaluating Acalabrutinib Monotherapy in Hematologic Malignancies (2017) (27)
Guideline for the treatment of chronic lymphocytic leukaemia (2018) (26)
Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study (2020) (26)
Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations (2021) (25)
Somatic mutation and clonal selection in the pathogenesis and in the control of paroxysmal nocturnal hemoglobinuria. (1998) (25)
Clonal lymphocytes in persons without known chronic lymphocytic leukemia (CLL): implications of recent findings in family members of CLL patients. (2004) (25)
CD52 expression in Waldenstrom's macroglobulinemia: implications for alemtuzumab therapy and response assessment. (2005) (25)
Final Analysis From the International Trial of Single-Agent Ofatumumab In Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia (2010) (24)
Analysis of T cells in paroxysmal nocturnal hemoglobinuria provides direct evidence that thymic T-cell production declines with age. (1999) (24)
appendix 6: Chronic lymphocytic leukaemia: eUpdate published online September 2016 (http://www.esmo.org/Guidelines/Haematological-Malignancies). (2016) (23)
Clinical and diagnostic implications of monoclonal B-cell lymphocytosis. (2010) (23)
An Open-Label Phase II Study to Investigate the Safety and Efficacy of Rituximab Plus Chlorambucil in Previously Untreated Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukaemia (CLL). (2009) (23)
Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study (2015) (22)
Outcomes with ibrutinib by line of therapy and post‐ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis (2019) (22)
Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) (2019) (22)
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. (2022) (22)
Acalabrutinib in Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL): Updated Results from the Phase 1/2 ACE-CL-001 Study (2018) (22)
Clinical and Immunological Characterisation of Coversin, a Novel Small Protein Inhibitor of Complement C5 with Potential As a Therapeutic Agent in PNH and Other Complement Mediated Disorders (2014) (21)
Acalabrutinib Monotherapy in Patients with Ibrutinib Intolerance: Results from the Phase 1/2 ACE-CL-001 Clinical Study (2016) (21)
The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial (2016) (21)
A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated chronic lymphocytic leukemia (CLL). (2013) (21)
Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1. (2020) (19)
Eradicating Minimal Residual Disease in Chronic Lymphocytic Leukemia: Should This Be the Goal of Treatment? (2010) (19)
How We Manage Patients With Chronic Lymphocytic Leukemia During the SARS-CoV-2 Pandemic (2020) (19)
Single‐agent ibrutinib versus chemoimmunotherapy regimens for treatment‐naïve patients with chronic lymphocytic leukemia: A cross‐trial comparison of phase 3 studies (2018) (19)
Interim Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab Plus Fludarabine in Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group). (2005) (19)
Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials (2018) (19)
Hematologic and Immunologic Function and Patient Well-Being for the Phase III RESONATETM Study of Ibrutinib Vs Ofatumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (2014) (19)
Minimal residual disease assessment in chronic lymphocytic leukaemia. (2007) (19)
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. (2022) (19)
SAMHD 1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage (2014) (19)
COVID‐19 infection in patients on anti‐complement therapy: The Leeds National Paroxysmal Nocturnal Haemoglobinuria service experience (2020) (19)
Five-Year Follow-up of Monoclonal B-Cell Lymphocytosis (MBL) in Individuals with a Normal Blood Count: Expansion of the Abnormal B-Cell Compartment but No Progressive Disease. (2009) (19)
Preliminary phase III efficacy and safety of alemtuzumab vs chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL). (2006) (19)
Safety, Efficacy and MRD Negativity of a Combination of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331) (2017) (19)
Minimal Residual Disease Is a Predictor for Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia (CLL) That Is Independent of the Type or Line of Therapy. (2009) (19)
Paroxysmal nocturnal hemoglobinuria: Correction of abnormal phenotype by somatic cell hybridization (1993) (18)
Health-related quality of life and patient-reported outcomes of ofatumumab plus chlorambucil versus chlorambucil monotherapy in the COMPLEMENT 1 trial of patients with previously untreated CLL (2016) (18)
Response: Additional data needed for a better understanding of the potential relationship between atrial fibrillation and ibrutinib. (2015) (18)
Clinical significance of DNA methylation in chronic lymphocytic leukemia patients: results from 3 UK clinical trials. (2019) (18)
Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial* (2016) (18)
TP53 Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia (2021) (18)
CLL-137 SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib Versus Bendamustine + Rituximab (BR) in Patients With Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/ SLL). (2021) (18)
Ibrutinib Plus Rituximab Is Superior to FCR in Previously Untreated CLL: Results of the Phase III NCRI FLAIR Trial (2021) (18)
The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab (2019) (18)
The Addition of Rituximab to Fludarabine and Cyclophosphamide (FC) Improves Overall Survival in Newly Diagnosed Mantle Cell Lymphoma (MCL): Results of the Randomised UK National Cancer Research Institute (NCRI) Trial (2011) (17)
Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies (2021) (17)
Pattern of Use of Anticoagulation and/or Antiplatelet Agents in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ibrutinib Therapy (2014) (17)
Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuate (2017) (17)
Up to seven years of follow-up in the RESONATE-2 study of first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. (2021) (17)
INTEGRATED ANALYSIS: OUTCOMES OF IBRUTINIB‐TREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LEUKEMIA (CLL/SLL) WITH HIGH‐RISK PROGNOSTIC FACTORS (2017) (17)
Outcomes with ibrutinib by line of therapy in patients with CLL: Analyses from phase III data. (2016) (17)
Clinical and morphological predictors of outcome in older aplastic anemia patients treated with eltrombopag (2019) (16)
Eculizumab in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Report of All 153 Patients Treated in the UK (2012) (16)
Immunophenotypic analysis of B cells in PNH: insights into the generation of circulating naive and memory B cells (2000) (16)
Serum erythropoietin levels in paroxysmal nocturnal haemoglobinuria: implications for therapy (1996) (16)
Clinical‐grade validation of whole genome sequencing reveals robust detection of low‐frequency variants and copy number alterations in CLL (2018) (16)
Expression of recombinant transmembrane CD59 in paroxysmal nocturnal hemoglobinuria B cells confers resistance to human complement. (1994) (16)
A multi‐centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T‐prolymphocytic leukaemia or mantle cell lymphoma (2018) (16)
Immunophenotypic Analysis of PNH Cells (2002) (16)
Concurrent treatment of aplastic anemia/paroxysmal nocturnal hemoglobinuria syndrome with immunosuppressive therapy and eculizumab: a UK experience (2018) (16)
Immunophenotypic analysis of B cells in PNH: insights into the generation of circulating naive and memory B cells. (2000) (16)
Extravascular Hemolysis Due to C3-Loading in Patients with PNH Treated with Eculizumab: Defining the Clinical Syndrome (2017) (16)
A randomized, multicenter, open-label, phase III study of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) versus ofatumumab in patients (pts) with relapsed or refractory (RR) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): RESONATE. (2013) (16)
Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial (2016) (16)
A comparison of the efficacy and safety of oral and intravenous fludarabine in chronic lymphocytic leukemia in the LRF CLL4 trial (2011) (16)
Erythropoietin treatment during complement inhibition with eculizumab in a patient with paroxysmal nocturnal hemoglobinuria (2007) (15)
Acalabrutinib, a second-generation bruton tyrosine kinase (Btk) inhibitor, in previously untreated chronic lymphocytic leukemia (CLL). (2016) (15)
High Definition Contrast-Enhanced MR Imaging in Paroxysmal Nocturnal Hemoglobinuria (PNH) Suggests a High Frequency of Subclinical Thrombosis. (2006) (15)
Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: Results from a phase 3, randomized, double-blind, placebo-controlled trial (2014) (15)
Clonal origin of abnormal granulocytes in paroxysmal nocturnal hemoglobinuria [letter; comment] (1992) (15)
Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial (2020) (15)
Immunological effects and safe administration of alemtuzumab (MabCampath™) in advanced B-CLL (2002) (14)
The STELLAR trial protocol: a prospective multicentre trial for Richter’s syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agents in relapsed disease (2019) (14)
Long-term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): Up to four years follow-up of the RESONATE study. (2017) (14)
Acalabrutinib in treatment-naïve chronic lymphocytic leukemia: Mature results from phase II study demonstrating durable remissions and long-term tolerability. (2020) (14)
Advances in the laboratory diagnosis of paroxysmal nocturnal hemoglobinuria (2001) (14)
Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients (2021) (14)
Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib (2018) (14)
Both paroxysmal nocturnal hemoglobinuria (PNH) type II cells and PNH type III cells can arise from different point mutations involving the same codon of the PIG-A gene. (1997) (14)
Outreach monitoring service for patients with indolent B‐cell and plasma cell disorders: a UK experience (2007) (14)
Autoimmune Hemolytic Anemia and Immune Mediated Thrombocytopenia in the Phase III RESONATETM Study of Ibrutinib Vs Ofatumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Including a Case Report (2014) (14)
Alemtuzumab (CAMPATH®, MABCAMPATH®) Has Superior Progression Free Survival (PFS) vs Chlorambucil as Front-Line Therapy for Patients with Progressive B-Cell Chronic Lymphocytic Leukemia (BCLL). (2006) (13)
Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed CLL. (2014) (13)
Eradication of minimal residual disease improves overall and progression‐free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation (2017) (13)
Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1-2 study. (2021) (13)
Integrative analysis of spontaneous CLL regression highlights genetic and microenvironmental interdependency in CLL. (2019) (13)
Nitric Oxide Consumption and Pulmonary Hypertension in Patients with Paroxysmal Nocturnal Hemoglobinuria. (2005) (13)
Safety and Efficacy of Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Have Undergone Prior Allogeneic Stem Cell Transplant (2014) (13)
Zanubrutinib in Combination with Venetoclax for Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Early Results from Arm D of the SEQUOIA (BGB-3111-304) Trial (2021) (13)
Presentation clinical, haematological and immunophenotypic features of 1081 patients with GPI‐deficient (paroxysmal nocturnal haemoglobinuria) cells detected by flow cytometry (2020) (13)
Altered natural killer cell subset homeostasis and defective chemotactic responses in paroxysmal nocturnal hemoglobinuria. (2013) (13)
Modification of the Eculizumab Dose to Successfully Manage Intravascular Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria. (2008) (13)
“Red Cell Complement Loading In PNH Patients On Eculizumab Is Associated With a C3 Polymorphism Which Influences C3 Function, Predicts For Increased Extravascular Hemolysis and Provides a Rationale For C3 Inhibition.” (2013) (12)
Ofatumumab retreatment and maintenance in fludarabine‐refractory chronic lymphocytic leukaemia patients (2015) (12)
Institute-Working Group (NCI-WG) 1996 guidelines Lymphocytic Leukemia (IWCLL) updating the National Cancer leukemia: a report from the International Workshop on Chronic Guidelines for the diagnosis and treatment of chronic lymphocytic (2008) (12)
CD52 expression patterns in myeloma and the applicability of alemtuzumab therapy. (2006) (12)
Improving cytopenia with splenic artery embolization in a patient with paroxysmal nocturnal hemoglobinuria on eculizumab (2013) (12)
Pharmacokinetics (PK) and pharmacodynamics (PD) of RG7112, an oral murine double minute 2 (MDM2) antagonist, in patients with leukemias and solid tumors. (2011) (12)
Assessment of human antihuman antibodies to eculizumab after long‐term treatment in patients with paroxysmal nocturnal hemoglobinuria (2016) (12)
Significant hemolysis is not required for thrombosis in paroxysmal nocturnal hemoglobinuria (2018) (12)
Correlation Between Serum Ofatumumab Concentrations, Baseline Patient Characteristics and Clinical Outcomes in Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ofatumumab. (2009) (11)
Gene Mutations and Treatment Outcome in CLL Patients Treated with Chlorambucil (Chl) or Ofatumumab-Chl (O-Chl): Results from the Phase III Study COMPLEMENT1 (OMB110911) (2013) (11)
Telomere length predicts for outcome to FCR chemotherapy in CLL (2019) (11)
11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies (2016) (11)
Risk factors for grade 3/4 transaminase elevation in patients with chronic lymphocytic leukemia treated with idelalisib (2017) (11)
MURANO Trial Establishes Feasibility of Time-Limited Venetoclax-Rituximab (VenR) Combination Therapy in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) (2018) (11)
SAMHD1 Limits the Efficacy of Forodesine in Leukemia by Protecting Cells against the Cytotoxicity of dGTP (2020) (10)
NCRI CLL201 Trial: A Randomized Phase II Trial of Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) with or without Rituximab in Previously Treated CLL. (2007) (10)
Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Results From the Randomized Phase III RESONATE™ (PCYC-1112) Trial (2015) (10)
Randomized comparison of ibrutinib versus ofatumumab in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the phase III RESONATE trial. (2014) (10)
Chronic lymphocytic leukaemia—moving towards cure? (2010) (10)
The incidence and prevalence of patients with paroxysmal nocturnal haemoglobinuria and aplastic anaemia PNH syndrome: A retrospective analysis of the UK’s population‐based haematological malignancy research network 2004‐2018 (2021) (10)
Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria: Pharmacokinetics and Pharmacodynamics Observed in Two Phase 3 Randomized, Multicenter Studies (2018) (9)
Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Follow-up Results from Arm C of the SEQUOIA (BGB-3111-304) Trial (2020) (9)
Ibrutinib for chronic lymphocytic leukemia: international experience from a named patient program (2018) (9)
Assessing minimal residual disease in chronic lymphocytic leukemia (2008) (9)
International Standardized Approach to Molecular and Flow Cytometric Residual Disease Monitoring in CLL. (2004) (9)
PAROXYSMAL nocturnal haemoglobinuria. (2010) (9)
ALPINE: Phase III zanubrutinib (BGB-3111) versus ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). (2019) (9)
for the COMPLEMENT 1 Study Investigators. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial (vol 385, pg 1873, 2015) (2016) (9)
An ultra-deep sequencing strategy to detect sub-clonal TP53 mutations in presentation chronic lymphocytic leukaemia cases using multiple polymerases (2016) (9)
Management of cardiovascular complications of bruton tyrosine kinase inhibitors (2021) (9)
Ibrutinib induces chromatin reorganisation of chronic lymphocytic leukaemia cells (2019) (9)
A five‐year follow‐up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil: final analysis of the Complement 1 phase 3 trial (2020) (9)
The Investigation of HMGA2 Dysregulation and Promoter Mutations in PIG-M in the Molecular Pathogenesis of Paroxysmal Nocturnal Haemoglobinuria (PNH). (2007) (9)
Blockade of Intravascular Hemolysis in PNH with the Terminal Complement Inhibitor Eculizumab Unmasks Low-Level Hemolysis Potentially Occurring through C3 Opsonization. (2006) (9)
Defective Modification of Mannose Residues by Terminal Phosphoethanolamine Underlies Inherited GPI Deficiency. (2005) (9)
Development of EBV-associated diffuse large B-cell lymphoma in Waldenström macroglobulinemia and mantle cell lymphoma (2008) (9)
Outcome of Ibrutinib Treatment by Baseline Genetic Features in Patients with Relapsed or Refractory CLL/SLL with del17p in the Resonate-17 Study (2015) (8)
LONG‐TERM EFFICACY AND SAFETY IN THE RESONATE STUDY: IBRUTINIB IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH UP TO FOUR YEARS FOLLOW‐UP (2017) (8)
Safety and Efficacy of the Terminal Complement Inhibitor Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Interim Shepherd Phase III Clinical Study. (2006) (8)
Single-Agent Ibrutinib Vs Chemoimmunotherapy Regimens for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia (CLL): A Cross-Trial Comparison (2017) (8)
The Bruton Tyrosine Kinase (Btk) Inhibitor ACP-196: Marked Activity in Relapsed/Refractory CLL with a Favorable Safety Profile (2015) (8)
Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (2016) (8)
Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1 (2020) (8)
Results from the Phase 3 DUOTM Trial: A Randomized Comparison of Duvelisib Vs Ofatumumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (2017) (8)
Richter transformation of chronic lymphocytic leukaemia: a British Society for Haematology Good Practice Paper (2021) (8)
Achieving a MRD negative response after alemtuzumab for CLL is the best predictor for prolonged survival (2003) (8)
Safety Profile of Venetoclax Monotherapy in Patients with Chronic Lymphocytic Leukemia (2016) (8)
Minimal residual disease and survival in chronic lymphocytic leukemia. (2005) (8)
Evaluation of Paroxysmal Nocturnal Hemoglobinuria Disease Burden: The Patient's Perspective. A Report From the International PNH Registry. (2010) (8)
The CXCR6/CXCL16 axis links inflamm-aging to disease severity in COVID-19 patients (2021) (8)
Prolonged Improvement in Patient-Reported Outcomes (PROs) and Well-being in Older Patients With Treatment-Naïve (TN) Chronic Lymphocytic Leukemia Treated With Ibrutinib (Ibr): 3-Year Follow-up of the RESONATE-2 Study (2017) (8)
Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) with 17p Deletion: Outcome and Minimal Residual Disease (MRD) from the Full Population of the Pivotal M13-982 Trial (2017) (8)
Compartment Effect on the Prognostic Significance of MRD Detection in CLL: Impact of Treatment Type and Duration of Follow-up (2016) (8)
Safety of acalabrutinib (Acala) monotherapy in hematologic malignancies: Pooled analysis from clinical trials. (2020) (8)
Beyond detectable minimal residual disease in chronic lymphocytic leukemia. (2006) (8)
Expression of recombinant transmembrane CD59 in paroxysmal nocturnal hemoglobinuria B cells confers resistance to human complement (1994) (8)
Clonal origin of abnormal granulocytes in paroxysmal nocturnal hemoglobinuria. (1992) (8)
Advancing Therapy For Chronic Lymphocytic Leukemia-the Role Of Rituximab. (2004) (8)
CLL-115 First Interim Analysis of ALPINE Study: Results of a Phase 3 Randomized Study of Zanubrutinib vs Ibrutinib in Patients With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). (2022) (7)
High Incidence of Progression to Chronic Renal Insufficiency in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). (2007) (7)
Long Term Safety and Efficacy of Sustained Eculizumab Treatment In Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) (2010) (7)
The Terminal Complement Inhibitor Eculizumab Reduces Thrombosis in Patients with Paroxysmal Nocturnal Hemoglobinuria. (2006) (7)
Ofatumumab in advanced stage chronic lymphocytic leukaemia: results of the UK named patient compassionate use programme (2011) (7)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib and Rituximab for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL) (2013) (7)
NCRN CLL207 Study of Alemtuzumab Consolidation In CLL: Final Response Assessment and Early Follow-up (on Behalf of the NCRI CLL Trials Sub-Group) (2010) (6)
Incidence of Genomic Aberrations and Associated Efficacy from a Phase III Study Comparing Alemtuzumab (CAMPATH®, MABCAMPATH®) vs Chlorambucil as First Line Therapy for B-Cell Chronic Lymphocytic Leukemia (BCLL). (2006) (6)
Long Term Survival Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab In Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group) (2010) (6)
Comparison of Oral and Intravenous Fludarabine in the LRF CLL4 Trial. (2005) (6)
An increased fraction of circulating miR-363 and miR-16 is particle bound in patients with chronic lymphocytic leukaemia as compared to normal subjects (2018) (6)
A Spontaneous Reduction of Clone Size in Paroxysmal Nocturnal Hemoglobinuria Patients Treated with Eculizumab for Greater Than 12 Months. (2009) (6)
Erythopoietin treatment during complement inhibition with eculizumab in a patient with paroxysmal nocturnal hemoglobinuria. (2007) (6)
High incidence of progression to chronic renal insufficiency in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) (2012) (6)
Eculizumab Reduces Pulmonary Hypertension through Inhibition of Hemolysis-Associated Nitric Oxide Consumption in Patients with Paroxysmal Nocturnal Hemoglobinuria (2008) (6)
Treatment with the Terminal Complement Inhibitor Eculizumab Improves Anemia in Patients with Paroxysmal Nocturnal Hemoglobinuria: Phase III Triumph Study Results. (2006) (6)
Dose adherence and baseline exposure analysis of the ibrutinib 420 mg dose administered to patients with previously treated chronic lymphocytic leukemia (CLL). (2015) (6)
Improved Outcomes of Budd-Chiari Syndrome in Paroxysmal Nocturnal Hemoglobinuria with Eculizumab Therapy (2012) (6)
A Multicenter, Phase IV Observational Study Of Ofatumumab In Chronic Lymphocytic Leukemia (CLL): A European Research Initiative On CLL (ERIC) Study (2013) (6)
TP53 Mutation or Deletion and Efficacy with Single-Agent Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009 Study) (2013) (6)
Sustained Improvements in Transfusion Requirements, Fatigue and Thrombosis with Eculizumab Treatment in Paroxysmal Nocturnal Hemoglobinuria. (2007) (6)
Improvement in Fatigue With Eculizumab Treatment of Patients With Paroxysmal Nocturnal Hemoglobinuria (pnh) Occurs Independent of Changes in Anemia (2008) (6)
Results of the Pegasus Phase 3 Randomized Trial Demonstrating Superiority of the C3 Inhibitor, Pegcetacoplan, Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria (2020) (6)
The initial report of the bloodwise tap clarity study combining ibrutinib and venetoclax in relapsed, refractory Cll shows acceptable safety and promising early indications of efficacy. (2017) (6)
Sudden or Cardiac Deaths on Ibrutinib-Based Therapy Were Associated with a Prior History of Hypertension or Cardiac Disease and the Use of ACE-Inhibitors at Study Entry: Analysis from the Phase III NCRI FLAIR Trial (2021) (6)
Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia (2021) (6)
Natural killer (NK) cell function in paroxysmal nocturnal hemoglobinuria: a deficiency of NK cells, but not an NK cell deficiency. (2015) (6)
A platform trial in practice: adding a new experimental research arm to the ongoing confirmatory FLAIR trial in chronic lymphocytic leukaemia (2021) (6)
FIRST RESULTS OF A HEAD‐TO‐HEAD TRIAL OF ACALABRUTINIB VERSUS IBRUTINIB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (2021) (6)
Updated Interim Results of the Safety and Efficacy of Different Lenalidomide Starting Dose Regimens in Patients with Relapsed or Refractory (rel/ref) Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009 Study) (2012) (5)
Health-related quality of life (HRQL) impact of idelalisib (IDELA) in patients (pts) with relapsed chronic lymphocytic leukemia (CLL): Phase 3 results. (2014) (5)
Outcomes of Ibrutinib Therapy By Age in Patients with CLL/SLL: Analyses from Phase 3 Trial Data (RESONATE and RESONATE-2) (2016) (5)
Minimal Residual Disease Status with Venetoclax Monotherapy Is Associated with Progression-Free Survival in Chronic Lymphocytic Leukemia (2018) (5)
Results Of The Randomised Phase II NCRI Arctic (Attenuated dose Rituximab with ChemoTherapy In CLL) Trial Of Low Dose Rituximab In Previously Untreated CLL (2013) (5)
Thrombotic Events with Neisseria Meningitidis Vaccination in Patients with Paroxysmal Nocturnal Hemoglobinuria, UK Experience (2020) (5)
Preliminary Safety and Efficacy Report of a Randomized Trial of Alemtuzumab vs Chlorambucil as Front-Line Therapy in 297 Patients with Progressive B-Cell Chronic Lymphocytic Leukemia. (2004) (5)
Future prospects for fludarabine-containing regimens in the treatment of hematological cancers. (2004) (5)
Results from the international, randomized phase 3 study of ibrutinib versus chlorambucil in patients 65 Years and older with treatment-naive (TN) CLL/SLL (RESONATE-2 (TM)) (2015) (5)
Final Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab Plus Fludarabine in Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group). (2006) (5)
Which patients with paroxysmal nocturnal hemoglobinuria (PNH) should be treated with eculizumab? ASH evidence-based review 2008. (2008) (5)
Ibrutinib and Obinutuzumab in CLL: Improved MRD Response Rates with Substantially Enhanced MRD Depletion for Patients with >1 Year Prior Ibrutinib Exposure (2018) (5)
Group 1996 guidelines Working - Lymphocytic Leukemia updating the National Cancer Institute leukemia: a report from the International Workshop on Chronic Guidelines for the diagnosis and treatment of chronic lymphocytic (2008) (5)
Phase 3 zanubrutinib (BGB-3111) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). (2018) (5)
Eradication of Minimal Residual Disease with Alemtuzumab in Chronic Lymphocytic Leukemia Is Associated with Prolonged Survival and Is an Appropriate Theraputic Endpoint for Relapsed CLL. (2007) (5)
Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial. (2022) (5)
Guideline for the treatment of chronic lymphocytic leukaemia (2022) (5)
Assessment of Eculizumab and C5 Levels in PNH Treatment: Molar Ratio of Eculizumab to C5 Level Effectively Predicts Ongoing Dosage Changes in a Cohort of 50 Patients Treated with Eculizumab (2017) (4)
Independent prognostic significance of minimal residual disease status in chronic lymphocytic leukaemia (2014) (4)
Pooled Analysis of Cardiovascular Events from Clinical Trials Evaluating Acalabrutinib Monotherapy in Patients with Chronic Lymphocytic Leukemia (CLL) (2020) (4)
A Prospective Analysis of Breakthrough Hemolysis in 2 Phase 3 Randomized Studies of Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria (2018) (4)
Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features (2022) (4)
Targeted therapy for chronic lymphocytic leukemia: a glimpse into the future. (2012) (4)
First Prospective Data on Impact of Minimal Residual Disease on Long-Term Clinical Outcomes after Venetoclax Plus Rituximab Versus Bendamustine Plus Rituximab: Phase III MURANO Study (2018) (4)
3113 – FORTY-EIGHT WEEK EFFICACY AND SAFETY OF PEGCETACOPLAN IN ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND SUBOPTIMAL RESPONSE TO PRIOR ECULIZUMAB TREATMENT (2021) (4)
Successful Pregnancy Outcomes in Paroxysmal Nocturnal Hemoglobinuria with Long-Term Eculizumab Treatment (2008) (4)
Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study) (2010) (4)
Disease Progression in Monoclonal B-Cell Lymphocytosis Is Independent of VH Mutation Status. (2006) (4)
Erratum: “Long‐term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinura” by Hillmen et al., Am J Hematol 553–559, 2010, DOI number 21757 (2010) (4)
Sustained Control of Hemolysis and Symptoms and Reduced Transfusion Requirements over a Period of 2 Years in Paroxysmal Nocturnal Hemoglobinuria (PNH) with Eculizumab Therapy. (2004) (4)
The Lack of Survival Differences in Randomised Trials in CLL May Be Related to the Effect of Second Line Therapies. A Report from the LRF CLL4 Trial. (2006) (4)
High, durable minimal residual disease negativity (MRD–) with venetoclax + rituximab (VenR) in relapsed/refractory (R/R) CLL: MRD kinetics from phase 3 MURANO study. (2018) (4)
Monoclonal B-Cell Lymphocytosis (MBL) and CLL Show Intraclonal Variation: Cases Classified as “Unmutated” Have the Greatest Clonal Diversity. (2006) (4)
COVID-19 vaccination antibody responses in patients with aplastic anaemia and paroxysmal nocturnal haemoglobinuria (2022) (4)
Advancing therapy for chronic lymphocytic leukemia--the role of rituximab. (2004) (4)
Pegcetacoplan versus Eculizumab in PNH. Reply. (2021) (4)
Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase 3 randomized trial. (2020) (4)
Molecular Mechanisms of Ibrutinib Resistance: Defining a Logical Approach to Improving Targeted Therapy in CLL (2016) (4)
Evolution of GPI-Deficient Clones Predicts Clinical Course in Paroxysmal Nocturnal Haemoglobinuria. (2004) (4)
Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (2019) (4)
Cytogenetic correlation with efficacy on alemtuzumab (CAM) vs chlorambucil (CHLO) as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL). (2006) (3)
Ofatumumab, a Novel CD20 Monoclonal Antibody, Is Active in Patients With Fludarabine- and Alemtuzumab-Refractory or Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia Irrespective of Prior Rituximab (2009) (3)
An In Vitro model of the Bone Marrow in Paroxysmal Nocturnal Hemoglobinuria Showing a Direct Effect of T-Cells within the Bone Marrow Allowing Clonal Expansion (2011) (3)
Idelalisib in Combination with Bendamustine/rituximab Improves Overall Survival in Patients with Relapsed/refractory Cll: Interim Results of a Phase 3 Randomized Double-Blind Placebo-Controlled Study (2016) (3)
The Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL: Updated Results from the DUO Crossover Extension Study (2018) (3)
A Phase 1b-2 Study of KRT-232, a First-in-Class, Oral, Small Molecule Inhibitor of Murine Double Minute 2 (MDM2), in Combination with Acalabrutinib for the Treatment of Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or R/R Diffuse Large B-Cell Lymphoma (DLBCL) (2020) (3)
Eculizumab for patients with paroxysmal nocturnal hemoglobinuria (PNH) is effective during the maintenance of hemodialysis for end stage renal failure. (2011) (3)
OP04 Safety and efficacy of the terminal complement inhibitor eculizumab in patients with paroxysmal nocturnal hemoglobinuria: Shepherd Phase III clinical study results (2007) (3)
Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study (2022) (3)
Patients with paroxysmal nocturnal hemoglobinuria demonstrate a prothrombotic clotting phenotype which is improved by complement inhibition with eculizumab (2020) (3)
Improvement in quality of life and well-being in older patients with treatment-naive (TN) CLL : results from the randomized phase 3 study of ibrutinib (IBR) versus chlorambucil (CLB) (resonate-2™) (2016) (3)
IMPACT OF MAJOR GENOMIC ALTERATIONS ON OUTCOME OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS RECEIVING VENETOCLAX PLUS RITUXIMAB IN THE PHASE 3 MURANO STUDY (2019) (3)
Effects of Eculizumab Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Concurrent Immunosuppressive Therapy for Bone Marrow Insufficiency. (2009) (3)
Presence of multiple recurrent mutations revealed by targeted NGS confers poor trial outcome of relapsed / refractory CLL (2015) (3)
The Level of Residual CLL Objectively Predicts the Outcome of Patients Following FCR-Based Therapy with Sequential Benefits per Log Depletion and Improved Post-Treatment Monitoring (2015) (3)
Management of Meningococcal Disease Risk in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) on Complement Inhibitors: 18 Years' Experience from the UK National PNH Service in Leeds (2020) (3)
DUO: a phase 3 trial of the PL3K-delta,gamma inhibitor IPI-145 versus ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphorytic lymphoma (2014) (3)
GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial (2017) (3)
Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study (2022) (3)
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial (2022) (3)
Multicenter, phase III, open-label, randomized study in relapsed/refractory CLL to evaluate the benefit of GDC-0199 (ABT-199) plus rituximab compared with bendamustine plus rituximab. (2014) (3)
Eculizumab Protects Against TE and Prolongs Survival in Patients with Paroxysmal Nocturnal Hemoglobinuria: An International PNH Registry Study (2012) (3)
Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase III randomized trial (2020) (3)
Zanubrutinib in Combination with Venetoclax for Patients with Treatment-Naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and del(17p): Arm D of the SEQUOIA (BGB-3111-304) Trial (2020) (3)
FINAL RESULTS OF THE NCRI CLL210 TRIAL OF ALEMTUZUMAB, DEXAMETHASONE AND LENALIDOMIDE IN PATIENTS WITH HIGH-RISK CLL (ORIGINAL PROTOCOL) (2016) (2)
A Validated Risk Model for Overall Survival in Relapsed/Refractory Chronic Lymphocytic Leukemia Applicable to Patients Treated with Novel Therapies and Standard of Care (2017) (2)
hemoglobinuria : sustained efficacy and improved survival Long-term treatment with eculizumab in paroxysmal nocturnal (2011) (2)
S145: THE COMBINATION OF IBRUTINIB PLUS VENETOCLAX RESULTS IN A HIGH RATE OF MRD NEGATIVITY IN PREVIOUSLY UNTREATED CLL: THE RESULTS OF THE PLANNED INTERIM ANALYSIS OF THE PHASE III NCRI FLAIR TRIAL (2022) (2)
Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study (2019) (2)
Assessment of the Clonal Dynamics of Acquired Mutations in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Treated in the Randomized Phase 3 Murano Trial Supports Venetoclax-Rituximab (VenR) Fixed-Duration Combination Treatment (Tx) (2021) (2)
SF3B1 mutations and outcome in CLL patients treated with chlorambucil (CHL) or ofatumumab-CHL (O plus CHL): results from the phase III study complement 1 (OMB110911) (2014) (2)
The efficacy of duvelisib monotherapy following disease progression on ofatumumab monotherapy in patients with relapsed/refractory CLL or SLL in the DUO crossover extension study. (2018) (2)
Specifi'c defect in N-acetylglucosamine incorporation in the biosynthesis of the glycosylphosphatidylinositol anchor in cloned cell lines from patients with paroxysmal nocturnal hemoglobinuria (2005) (2)
Chronic Lymphocytic Leukaemia and Other Chronic B‐Cell Disorders (2015) (2)
Improvement in hematologic function, disease burden/symptoms with ibrutinib in older treatment-naive (TN) patients with chronic lymphocytic leukemia (CLL) in phase 3 RESONATE-2 (TM) (2016) (2)
Analysis of Quality of Life and Well-being from the Randomized Phase 3 Study of Ibrutinib Versus Chlorambucil in Older Patients with Treatment-naïve CLL (RESONATE-2TM) (2016) (2)
CD52 Expression Patterns in Normal and Neoplastic B-Cells: Myeloma Is an Unlikely Target for Single Agent Alemtuzumab Therapy. (2004) (2)
Mutational Landscape of 118 Relapsed Chronic Lymphocytic Leukemia Clinical Trial Samples; Evidence for a Multiple-Hit Profile Using Targeted Next Generation Sequencing (2014) (2)
Laboratory Diagnosis of Chronic Lymphocytic Leukaemia (2019) (2)
MBL and MoBL – Response to Ziegler‐Heitbrock (2005) (2)
Analysis of Prognostic Factors Predictive of Complete Response (CR) to Ibrutinib in Patients with CLL/SLL (2015) (2)
PP-054 EFFICACY OF IDELALISIB IN CLL SUBPOPULATIONS HARBORING DEL(17P) AND OTHER ADVERSE PROGNOSTIC FACTORS: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (2014) (2)
Clinical characteristics of classic Paroxysmal Nocturnal Hemoglobinuria (PNH) in pediatric patients: a comparison with classic PNH in adults. An international PNH registry study (2011) (2)
Presentation Clinical, Haematological and Immunophenotypic Features of 1081 Patients with GPI-deficient (PNH) cells detected by flow cytometry (2021) (2)
Safety and Efficacy of Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Who Have Undergone Prior Allogeneic Stem Cell Transplant (2015) (2)
UNFAVORABLE GENETICS IMPACT MRD RESPONSE TO VENETOCLAX+RITUXIMAB RETREATMENT IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL): PHASE 3 MURANO SUBSTUDY (2021) (2)
DAPK3 participates in the mRNA processing of immediate early genes in chronic lymphocytic leukaemia (2020) (2)
SINGLE ARM NCRI FEASIBILITY PHASE II STUDY OF CHOP IN COMBINATION WITH OFATUMUMAB IN INDUCTION AND MAINTENANCE FOR PATIENTS WITH NEWLY DIAGNOSED RICHTER'S SYNDROME (2015) (2)
AN IMPROVED BENEFIT‐RISK PROFILE OF DUVELISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA WHO RECEIVED 2 OR MORE PRIOR THERAPIES (2019) (2)
Use of Blood Transfusions In Paroxysmal Nocturnal Hemoglobinuria Patients with and without Aplastic Anemia Enrolled In the Global PNH Registry (2010) (2)
Identifying High-Risk CLL to Predict Early Relapse after FCR Based Treatment Using Whole Genome Sequencing: First Results from the Genomics England CLL Pilot (2016) (2)
Impact of prognostic factors on outcome in a phase III study comparing alemtuzumab to chlorambucil as first-line therapy for B-cell chronic lymphocytic leukemia (BCLL) (2007) (2)
BONE MARROW IS MORE SENSITIVE THAN PERIPHERAL BLOOD FOR DETECTION OF MRD IN CLL AND PROVIDES A MORE RELIABLE PREDICTION OF OUTCOME ACROSS DIFFERENT TREATMENTS (2015) (2)
Addition of Obinutuzumab to Ibrutinib Enhances Depletion of CLL Cells in the Peripheral Blood and Bone Marrow after 1 Month of Combination Therapy: Initial Results from the Bloodwise TAP Iciclle Extension Study (2016) (2)
Subcutaneous Alemtuzumab Has Activity in Treatment-Naïve Patients with Acquired Aplastic Anemia (2019) (2)
Highly selective SYK inhibitor, GSK143, abrogates survival signals in chronic lymphocytic leukaemia (2018) (2)
RITUXIMAB PLUS CHLORAMBUCIL (R-CHLORAMBUCIL) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): FINAL ANALYSIS OF AN OPEN-LABEL PHASE II STUDY (2011) (2)
Polymyalgia rheumatica development in a patient under PI3K inhibitor therapy for chronic lymphocytic leukaemia (2017) (2)
Clinical and Biological Indicators of Duvelisib Efficacy in CLL from the Phase 3 DUOTM Study (2018) (2)
Enhancing care and managing side effects in patients receiving bortezomib. (2006) (2)
Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies (2021) (2)
SAMHD1 limits the efficacy of forodesine in leukaemia by protecting cells against cytotoxicity of dGTP (2020) (1)
Effect of eculizumab treatment in patients with paroxysmal nocturnal hemoglobinuria with or without high disease activity: Real‐world findings from the International Paroxysmal Nocturnal Hemoglobinuria Registry (2022) (1)
Home Infusion of Eculizumab: A Unique and Innovative Model of Drug Delivery to Reduce Treatment-Associated Burden and Enhance Quality of Life for Patients with PNH (2008) (1)
Thrombosis in Non-Hemolytic Paroxysmal Nocturnal Haemogloinuria (2017) (1)
Erratum: Ofatumumab, a novel CD20 monoclonal antibody, is active in patients with fludarabine- and alemtuzumab-refractory or bulky fludarabine-refractory chronic lymphocytic leukemia irrespective of prior rituximab (Clinical lymphoma & Myeloma (2009) 9: 6 (E36) DOI: 10.3816/CLM.2009.n.098) (2010) (1)
Multicentre Genome Wide Association Study Identifies Risk Alleles for Progressive Chronic Lymphocytic Leukaemia (2019) (1)
Coversin, a small protein complement inhibitor, is a potential novel anti-thrombotic agent (2014) (1)
RESULTS OF THE PEGASUS PHASE 3 RANDOMIZED TRIAL DEMONSTRATING SUPERIORITY OF THE C3 INHIBITOR PEGCETACOPLAN COMPARED TO ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (2020) (1)
Analysis of Baseline Clinical Characteristics and Disease Burden in Patients Enrolled in the International Paroxysmal Nocturnal Hemoglobinuria Registry (2017) (1)
Update in paroxysmal nocturnal hemoglobinuria. (2012) (1)
MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study (2022) (1)
Paroxysmal Nocturnal Hemoglobinuria in Pregnancy (2015) (1)
Duvelisib inhibition of chemokines in patients with CLL (DUO study) and iNHL (DYNAMO study). (2018) (1)
Final analysis from RESONATE: Six-year follow-up in patients (pts) with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) on ibrutinib. (2019) (1)
Optimising alemtuzumab therapy for refractory B cell chronic lymphocytic leukaemia (CLL). (2004) (1)
Paroxysmal Nocturnal Hemoglobinuria— the Selection of a Clone (2000) (1)
Real‐world treatment patterns, adverse events and clinical outcomes in patients with chronic lymphocytic leukaemia treated with ibrutinib in the UK (2021) (1)
Increased Expression of CD200 Antigen, a Potential Immunotherapeutic Target, Is Consistently Found in CLL Cells Irrespective of Biological Features. (2006) (1)
Cellulose Sulfate for Prevention of HIV Infection (2008) (1)
The correlation between the eradication of minimal residual disease (MRD) following alemtuzumab for CLL and overall survival. (2004) (1)
Patterns of Lymphocytosis in Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Treated with Idelalisib (2015) (1)
The LLR TAP IcICLLe trial assessing biological response to ibrutinib in CLL: Immediate disease redistribution precedes cell cycle arrest by 2 weeks with reduced bone marrow infiltration by 6 months (2015) (1)
S146: VENETOCLAX IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION: 6-YEAR FOLLOW-UP AND GENOMIC ANALYSES IN A PIVOTAL PHASE 2 TRIAL (2022) (1)
Chronic lymphocytic leukemia--aiming at a moving target! (2005) (1)
Review in translational hematology Diagnosis and management of paroxysmal nocturnal hemoglobinuria (2005) (1)
IgH Rearrangements and Mutational Status in Class-Switched IgG B-CLL. (2004) (1)
British Committee for Standards in Haematology guidelines for aplastic anemia: Single centre retrospective review finds no compelling evidence for the recommended higher platelet count threshold of 20 × 109/L ‐ RESPONSE to Yan et al (2018) (1)
S107 FIVE-YEAR FOLLOW-UP OF PATIENTS RECEIVING IBRUTINIB FOR FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (2019) (1)
Defining response criteria in CLL patients treated in clinical research trials Response (2010) (1)
P662: PATIENT-REPORTED OUTCOMES FROM A PHASE 3 RANDOMIZED STUDY OF ZANUBRUTINIB VERSUS BENDAMUSTINE PLUS RITUXIMAB (BR) IN PATIENTS WITH TREATMENT-NAÏVE (TN) CLL/SLL (2022) (1)
Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Murano Trial (2019) (1)
The LLR TAP IcICLLe Trial: detailed assessment of the response to ibrutinib provides insights into the mode of action and pattern of response in treatment nayve and refractory CLL. (2015) (1)
Population Pharmacokinetics of Alemtuzumab in Patients with Hematologic Malignancies. (2005) (1)
Bi-Allelic Deletion of 13q14 Is Associated with Inferior Progression Free Survival Compared to Mono-Allelic 13q14 Deletion in B-Cell Chronic Lymphocytic Leukaemia. (2005) (1)
Real-World Treatment Patterns and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib in the UK: A Preliminary Analysis (2019) (1)
Response: Letters regarding Blood. 2008;111:5446-5456 by Hanson et al and Mulligan et al (2009) (1)
Alpine: Phase 3 Trial of Zanubrutinib (BGB-3111) Vs Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (2019) (1)
Obinutuzumab as consolidation after chemo‐immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial (2022) (1)
Long-term follow-up of previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) treated with ofatumumab (OFA) and chlorambucil (CHL): Final analysis of the phase 3 COMPLEMENT 1 trial. (2019) (1)
P663: HEALTH-RELATED QUALITY OF LIFE OUTCOMES ASSOCIATED WITH ZANUBRUTINIB VS IBRUTINIB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (RR) CLL/SLL: RESULTS FROM THE RANDOMIZED PHASE 3 ALPINE TRIAL (2022) (1)
Trial re-investment to build better research for better impact (2019) (1)
Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial. (2020) (1)
the treatment of patients with paroxysmal nocturnal hemoglobinuria Multicenter phase 3 study of the complement inhibitor eculizumab for (2008) (1)
Continued Benefit From Prolonged Treatment with Eculizumab in 130 Patients with PNH in the UK: Home Delivery of Eculizumab Is Safe, Convenient and Associated with Very High Levels of Patient Satisfaction (2011) (1)
Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial (2016) (1)
The correlation between the eradication of minimal residual disease (MRD) following alemtuzumab for CLL and overall survival (2004) (1)
The clinical benefit of eculizumab is demonstrable in all subpopulations of patients with paroxysmal nocturnal hemoglobinuria (PNH) with hemolysis (2007) (1)
Haematologic and immunologic function and patient-reported outcomes for the phase 3 RESONATE (TM) study of ibrutinib versus ofatumumab in relapsed/refractory chronic lymphocytic leukaemia/small lymphocytic lymphoma (2015) (1)
Insights Into The Natural History Of Paroxysmal Nocturnal Hemoglobinuria (PNH): Analysis Of The Presenting Clinical, Haematological and Flow Cytometric Features Of 705 Patients Leads To Improved Classification and Prediction Of Clinical Course (2013) (1)
Richter's syndrome: CLL taking a turn for the worse. (2012) (1)
A phase II study of MOR208 plus idelalisib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously treated with a Bruton's tyrosine kinase inhibitor (MIRACLE). (2016) (1)
Recurrent Gene Mutations and Clinical Outcome in the Context of Lenalidomide Treatment of Relapsed/Refractory CLL — Results from Multicenter Phase II Trial CLL-009 (2017) (1)
Reproducible diagnosis of CLL by flow cytometry: an ERIC & ESCCA harmonisation project (2015) (1)
Ibrutinib and Obinutuzumab in CLL: MRD Responses Sustained for Several Years with Deepest MRD Depletion in Patients with >1 Year Prior Ibrutinib Exposure (2020) (1)
Safety and efficacy of eculizumab with concomitant erythropoietin therapy in patients with paroxysmal nocturnal hemoglobinuria (PNH) (2007) (1)
RANDOMIZED COMPARISON OF IBRUTINIB VERSUS OFATUMUMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA / SMALL LYMPHOCYTIC LYMPHOMA: RESULTS FROM THE PHASE III PCYC-1112 RESONATE((TM)) TRIAL (2014) (1)
responses in paroxysmal nocturnal hemoglobinuria Altered natural killer cell subset homeostasis and defective chemotactic (2013) (1)
Ofatumumab retreatment and maintenance in patients with fludarabine-refractory CLL. (2012) (1)
Patterns of hepatitis B reactivation and liver test abnormalities in patients with chronic lymphocytic leukemia (CLL) treated with idelalisib plus an anti-CD20 antibody. (2016) (1)
Concurrent Treatment of Aplastic Anaemia (AA) with Immunosuppressive Therapy and Paroxysmal Nocturnal Hemoglobinuria (PNH) with Eculizumab: A UK Experience (2016) (1)
Long‐term follow‐up of 415 patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide‐based chemoimmunotherapy in the frontline ADMIRE and ARCTIC trials: A comprehensive assessment of prognostic factors (2022) (1)
The Effect of Eculizumab Therapy on Red Cell Response Kinetics in Patients with Paroxysmal Nocturnal Hemoglobinuria. (2005) (1)
Pegcetacoplan Is Superior to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria Regardless of Prior Transfusion Requirement (2020) (1)
Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib Alone or in Combination with Idelalisib or Entospletinib in Patients with Previously Treated Chronic Lymphocytic Leukemia (2018) (1)
Long term outcomes in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) with sustained eculizumab treatment (2012) (1)
Efficacy of coxsackievirus A21 against drug-resistant neoplastic B cells. (2023) (0)
CLL-045: Long-Term Follow-up, Up to 7 Years, in the RESONATE-2 Study of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL) (2021) (0)
High-Sensitivity Analysis of Normal B-Cell Subsets in MBL and Untreated CLL Identifies Patients with Sub-Optimal Sars-Cov-2 Antibody Responses (2022) (0)
Suppl-Resonate-2-Burger-2015 (2016) (0)
1 Diagnosis and Management of Paroxysmal Nocturnal Hemoglobinuria : (2005) (0)
COSMIC, chemotherapy plus ofatumumab at standard or mega‐dose in chronic lymphocytic leukaemia, a phase II randomised study (2021) (0)
Aberrant Expression of Neuronal Receptors in CLL: Potential Targets with Therapeutic Implications (2012) (0)
O2-11-2Efficacy and safety in genetic and clinical subgroups: Phase III RESONATETM trial of ibrutinib vs ofatumumab in CLL/SLL (2015) (0)
Five-Year Follow-Up After Ibrutinib Therapy for First-Line Treatment of Chronic Lymphocytic Leukemia (2019) (0)
Characterization of Bruton Tyrosine Kinase Inhibitor (BTKi)-Related Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL) (2021) (0)
Consolidating MRD and survival in CLL (2006) (0)
Ibrutinib plus venetoclax in Relapsed/Refractory CLL: The CLARITY Study (2020) (0)
Abstract CT532: Phase 1/2 results of ceralasertib (Cerala) as monotherapy or in combination with acalabrutinib (Acala) in high-risk relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) (2022) (0)
Response : Interpretation of sequential minimal residual disease assessment in chronic lymphocytic leukemia (0)
EBV Related Transformation Events in CLL. (2006) (0)
Incomplete Complement Inhibition in Patients with PNH on Eculizumab - 5 Year Experience from the National PNH Service Leeds (2020) (0)
Evaluation of Immune Mechanisms to Understand Idelalislib-Associated Diarrhea-Colitis (2016) (0)
A phase I trial of the PARP inhibitor olaparib in patients with relapsed or refractory Chronic Lymphocytic Leukaemia, T-Prolymphocytic Leukaemia or Mantle Cell Lymphoma (2018) (0)
Interpretation of sequential minimal residual disease assessment in chronic lymphocytic leukemia (2017) (0)
Congenital paroxysmal nocturnal haemoglobinuria (1999) (0)
Risk Model for Overall Survival for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Validated for Patients on Ibrutinib, Idelalisib, Venetoclax, or Chemoimmunotherapy (2018) (0)
SAMHD1, A Putative Tumour Suppressor, Is Recurrently Mutated in Chronic Lymphocytic Leukaemia, and Is Associated with Poor Risk Features (2012) (0)
MRD in CLL. (2006) (0)
International, randomized phase 3 study results : Ibrutinib versus Chlorambucil in patients 65 years and older with treatment-naive CLL (RESONATE-2 (TM)) (2016) (0)
The STELLAR trial protocol: a prospective multicentre trial for Richter’s syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agents in relapsed disease (2019) (0)
Outcomes with Ibrutinib by Line of Therapy in Patients with CLL: Analyses from Phase 3 Data (2016) (0)
Comprehensive genomic testing for chronic lymphocytic leukaemia patients: WGS, one key to patient stratification (2020) (0)
MBL and MoBL - Response (2005) (0)
3.14 The Influence of Genetic Background and Infectious Exposure on the Development of Chronic Lymphocytic Leukaemia and Other B-Cell Malignancies: Evidence from High-Sensitivity Screening in Leeds and Rural Uganda (2011) (0)
CT-286: Results of the PEGASUS Phase 3 Randomized Trial Demonstrating Superiority of the C3 Inhibitor, Pegcetacoplan, Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria (2020) (0)
An Improved Benefit-Risk Profile of Duvelisib in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Received ≥2 Prior Therapies (2019) (0)
It is recommended that you download this PDF to your computer for furture reference. It spells out how CLL is treated clinically. (2008) (0)
Defective Telomerase in Familial Myelodysplasia and Leukemia (2008) (0)
Genomic Disruption of the Histone Methyltransferase SETD2 in Chronic Lymphocytic Leukemia (2015) (0)
FIVE‐YEAR FOLLOW‐UP OF FIRST‐LINE IBRUTINIB FOR TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA//SMALL LYMPHOCYTIC LYMPHOMA (2019) (0)
An open-label phase II study to investigate the safety and efficacy of rituximab plus chlorambucil in previously untreated patients with CD20-positive B-cell chronic lymphocytic leukaemia (CLL): On behalf of the NCRI CLL sub-group (2010) (0)
A SMALL PROTEIN THAT INHIBITS COMPLEMENT ACTIVITY PROVIDES A POTENTIAL NOVEL ANTI-THROMBOTIC AGENT (2014) (0)
Telomere Length and CD49d Cooperate with IGHV Gene Status As Predictors of Long-Term Progression-Free Survival in CLL Patients Treated with FCR-Based Regimens (2020) (0)
COVID-19 Vaccination Responses in Patients With Aplastic Anaemia and Paroxysmal Nocturnal Haemoglobinuria; Results From the UK (Leeds) PNH National Service Prospective Study (2022) (0)
COSMOS: MOR208 plus idelalisib or venetoclax in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously treated with a Bruton's tyrosine kinase inhibitor (BTKi)—A two-cohort phase II study. (2017) (0)
TP53 Deletion in CLL: The Significance of Borderline Level Deletion (2008) (0)
MDS-134: Efficacy and Safety at 48 Weeks of Pegcetacoplan in Adult Paroxysmal Nocturnal Hemoglobinuria Patients with Suboptimal Response to Prior Eculizumab Treatment (2021) (0)
Lymphoma: Small lymphocytic lymphoma/chronic lymphocytic leukemia (2013) (0)
Highly Comprehensive Genomic Testing for CLL: WGS, One Key to CLL Patient Stratification (2018) (0)
chronic lymphocytic leukemia Perspectives on the use of new diagnostic tools in the treatment of (2013) (0)
Experiences in the design and implementation of phase II trials in CLL (2011) (0)
Lack of correlation of eculizumab therapy in paroxysmal nocturnal hemoglobinuria (PNH) patients with myeloproliferative disorders, myelodysplastic syndromes, acute leukemias or aplastic anemia with long-term treatment (2008) (0)
Phase 3 Study of Ibrutinib versus Chlorambucil in Patients ≥65 Years with Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (2016) (0)
Safety and efficacy of eculizumab in paroxysmal nocturnal hemoglobinuria evolving from patients with myelodysplastic syndrome and aplastic anemia (2007) (0)
Improved Health-Related Quality of Life in Patients with Chronic Lymphocytic Leukemia Treated with Ofatumumab Plus Chlorambucil or Chlorambucil (2014) (0)
Many People With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Benefit From Ibrutinib Treatment Up To 8 Years: A Plain Language Summary. (2023) (0)
EFFECT OF ADDING IDELALISIB TO FRONTLINE OFATUMUMAB PLUS EITHER CHLORAMBUCIL OR BENDAMUSTINE IN LESS FIT PATIENTS WITH CLL: PRELIMINARY RESULTS FROM THE NCRI RIALTO TRIAL. (2017) (0)
Acquired Aplastic Anaemia and Paroxysmal Nocturnal Haemoglobinuria (2015) (0)
Lessons from an incidental diagnosis of paroxysmal nocturnal haemoglobinuria (2012) (0)
A comparison of oral and intravenous fludarabine in the LRF CLL4 trial (on behalf of the UKNCRI CLL trials group) (2006) (0)
BRIEF CO‐ADMINISTRATION OF IDELALISIB MAY IMPROVE THE LONG‐TERM EFFICACY OF FRONTLINE CHEMOIMMUNOTHERAPY IN CHRONIC LYMPHOCYTIC LEUKAEMIA: 3‐YEAR FOLLOW‐UP FROM THE RIALTO TRIAL (2019) (0)
P791: COMMON VARIANTS IN COMPLEMENT PROTEINS, C3 AND CR1, ENHANCE COMPLEMENT ATTACK ON PNH ERYTHROCYTES AND INCREASE RISK FOR EXTRAVASCULAR HAEMOLYSIS (2022) (0)
4.25 Update on the International Standardized Approach for Flow Cytometric Residual Disease Monitoring in CLL (2011) (0)
PS1123 IMPACT OF MAJOR GENOMIC ALTERATIONS ON OUTCOME OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH VENETOCLAX PLUS RITUXIMAB IN THE PHASE 3 MURANO STUDY (2019) (0)
Clinico-biological significance of DNA methylation in chronic lymphocytic leukaemia patients: results from three UK clinical trials (2020) (0)
Histopathology, Morphology and Immunophenotyping of CLL (2013) (0)
Optimising alemtuzumab therapy for refractory B cell chronic lymphocytic leukaemia (CLL) (2004) (0)
An increased fraction of circulating miR-363 and miR-16 is particle bound in patients with chronic lymphocytic leukaemia as compared to normal subjects (2018) (0)
Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. (2023) (0)
USP 7 inhibition alters homologous recombination repair and targets CLL cells independent of ATM / p 53 functional status Running title : USP 7 INHIBITION TARGETS ATM AND P 53 DEFECTIVE CLL (2017) (0)
5.46 NCRN CLL207 Study of Alemtuzumab Consolidation in Chronic Lymphocytic Leukaemia: Response Assessment Follow-up and Pharmacokinetic studies (on Behalf of the NCRI CLL Trials Sub-Group) (2011) (0)
A Phase II randomised study investigating the efficacy of standard Or high-dose Ofatumumab in combination with chemotherapy in relapsed chronic lymphocytic leukaemia. (2017) (0)
No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisib (2020) (0)
Subject Index Vol. 108, 2002 (2002) (0)
2012 American Society of Hematology report: advances in paroxysmal nocturnal hemoglobinuria (2013) (0)
Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia (2021) (0)
Ibrutinib for first-line treatment of chronic lymphocytic leukemia in patients aged >= 65 year of age : results with 5 years of follow-up for the RESONATE-2 study (2020) (0)
The Bloodwise TAP Calibre Feasibility Study to Assess the Mechanism of Action of Idelalisib in B-Cell Receptor Pathway (BCR) Inhibition in Chronic Lymphocytic Leukaemia (CLL) (2017) (0)
Age group General population Normal relatives from CLL families Relative risk (95% CI) P-value (Fisher's exact test) (2006) (0)
Evaluation of risk for development of myeloproliferative disorders, myelodysplastic syndromes, or acute leukemias with long-term eculizumab therapy in paroxysmal nocturnal hemoglobinuria (PNH) patients (2007) (0)
161A point mutation in an Sp1 binding motif in the promoter of the mannosyltransferase-encoding PIG-M gene causes inherited glycosylphosphatidylinositol deficiency (2007) (0)
Whole genome sequencing in the clinic identifies CLL patients with high risk of relapse: pilot study for the 100,000 Genomes Project (2018) (0)
Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with CLL: phase 3 analysis (2019) (0)
nejmoa1509981 appendix (1) (2016) (0)
Fibrinogen and Clot Structure Is Affected By Eculizumab in Patients with Paroxysmal Nocturnal Haemoglobinuria (2017) (0)
Telomere length and POT1 mutations in CLL: incidence, associations and clinical impact in the Complement 1 trial (2015) (0)
Linking genotype to clinical phenotype through proteomic analysis of CLL trial samples (2017) (0)
P673: DEPLETION AND RECOVERY OF NORMAL B-CELLS DURING AND AFTER TREATMENT WITH CHEMOIMMUNOTHERAPY, IBRUTINIB OR VENETOCLAX. (2022) (0)
Title Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (2019) (0)
Monoclonal B-Cell Lymphocytosis (MBL) Is a Precursor State for Chronic Lymphocytic Leukemia (CLL) with 1% Progression Per Year. (2007) (0)
Differential Protein Expression in MBL and CLL: LAIR1 Is a Powerful Surface Marker for Identifying Cases with Adverse Cellular Features. (2008) (0)
FIRST‐LINE TREATMENT WITH IBRUTINIB FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): 7‐YEAR RESULTS FROM RESONATE‐2 (2021) (0)
Management of paroxysmal nocturnal haemoglobinuria in the eculizumab era: the bedside and beyond (2008) (0)
Fludarabine plus cyclophosphamide combination: a new standard for first-line therapy in chronic lymphocytic leukaemiaa (2009) (0)
The biochemical and cellular basis of paroxysmal nocturnal haemoglobinuria. (1995) (0)
Differing Mutational Profiles of IgHV(+) and IgHV Patients Revealed By Whole Genome Sequencing in Chronic Lymphocytic Leukaemia (CLL) (2016) (0)
2.48 Identification and Validation of Potential Targets for the Diagnosis and Therapy of CLL (2011) (0)
Codon of the Type III Cells Can Arise From Different Point Mutations Involving the Same Both Paroxysmal Nocturnal Hemoglobinuria (PNH) Type II Cells and PNH (2011) (0)
Ibrutinib vs Clorambucilo-Burger-2015-e-pub (2016) (0)
Telomere Length Predicts for Outcome to FCR Chemoimmunotherapy in CLL (2018) (0)
Adherence To The Ibrutinib 420 mg Dose Administered To Patients With Previously Treated CLL (2015) (0)
Paroxysmal nocturnal haemoglobinuria (PNH)iscaused bysomatic mutations inthePIG-Agene (1994) (0)
The Identification of Further Minimal Regions of Overlap in Chronic Lymphocytic Leukemia Using High-Resolution SNP Arrays (2014) (0)
Towards Response Prediction Using Integrated Genomics in Chronic Lymphocytic Leukaemia: Results on 250 First-Line FCR Treated Patients from UK Clinical Trials (2014) (0)
Epigenomic evolution in chronic lymphocytic leukaemia cells from patients treated with ibrutinib and showing disease progression (2020) (0)
IDELALISIB PLUS AN ANTI-CD20 ANTIBODY IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO ARE HBV CORE ANTIBODY POSITIVE: SIMILAR PATTERNS OF LIVER TEST ABNORMALITIES (2016) (0)
Lymphoma: Small lymphocytic lymphoma and its variants (2007) (0)
Contents Vol. 108, 2002 (2002) (0)
Long-term safety and efﬁcacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria (2013) (0)
Immunophenotypic assessment of PNH clones in major and minor cell lineages in the peripheral blood of patients with paroxysmal nocturnal hemoglobinuria (2022) (0)
A Complementary Role of High Throughput Sequencing and Multiparameter Cytometry for Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL):an European Research Initiative (ERIC) Study (2014) (0)
Therapeutic role of dopamine receptors expressed on chronic lymphocytic leukaemia (CLL) cells (2013) (0)
The role of alemtuzumab in the treatment of chronic lymphocytic leukemia (CLL) and the achievement of minimal residual disease negativity in relapsed/refractory CLL (2009) (0)
LINKING PROTEOME AND GENOME FOR BIOMARKER DISCOVERY IN CLL-ESTABLISHMENT OF A CLL PROTEIN DATABASE (2016) (0)
A Ibrutinib results in reduction of phosphorylation of multiple kinases in the B-Cell receptor pathway in chronic lymphocytic leukaemia (Cll): results of the Bloodwise Tap Iciclle study (2017) (0)
A Global Registry of Patients with Paroxysmal Nocturnal Hemoglobinuria. (2009) (0)
Abstract 3306: The clinical importance of DNA methylation signatures in chronic lymphocytic leukemia patients treated with chemo-immunotherapy (2018) (0)
Second Interim Analysis of a Phase 3 Study Evaluating Idelalisib and Rituximab for Relapsed Chronic Lymphocytic Leukemia (2014) (0)
CD5-Negative Monoclonal B-Cell Lymphocytosis (MBL) Is Detectable In 9% of Adults Aged Over 40 but Phenotypes Associated with Clinically Common Non-Hodgkin Lymphomas Are Infrequent (<2%) (2010) (0)
Ibrutinib mediates changes in chromatin structure in chronic lymphocytic leukaemia (CLL): epigenetic studies from the bloodwise TAP IcICLLe trial (2017) (0)
B-lymphocyte expansion Inherited predisposition to CLL is detectable as sub-clinical monoclonal (2013) (0)
Kinobead Profiling Reveals Reprogramming of BCR Signaling in Response to Therapy within Primary CLL Cells (2021) (0)
CLL-115: First Results of a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (2021) (0)

This paper list is powered by the following services:

Other Resources About Peter Hillmen

medhealth.leeds.ac.uk

What Schools Are Affiliated With Peter Hillmen?

Peter Hillmen is affiliated with the following schools:

Peter Hillmen's Academic­Influence.com Rankings

Peter Hillmen's Degrees

Why Is Peter Hillmen Influential?

Peter Hillmen's Published Works

Published Works

Other Resources About Peter Hillmen

What Schools Are Affiliated With Peter Hillmen?

Peter Hillmen's AcademicInfluence.com Rankings